Tirzepatide (Mounjaro)

Tirzepatide, sold under the brand name Mounjaro, is a once-weekly injection that helps with weight loss by mimicking two natural hormones that control appetite and blood sugar. It works on both GLP-1 and GIP receptors, making it one of the most effective weight loss medications available today.

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. In the SURMOUNT-1 trial, participants lost up to 22.5% of body weight at 72 weeks with the 15 mg dose. It acts on both incretin pathways to reduce appetite, delay gastric emptying, and improve insulin sensitivity. Common side effects include nausea, diarrhoea, and decreased appetite, typically most pronounced during dose escalation.

Tirzepatide represents the next generation of medical weight loss treatment, offering results approaching bariatric surgery. Dr. Joseph Wang can assess whether this medication is suitable for your weight management programme.